A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
This study has been withdrawn prior to enrollment.
First Posted: July 17, 2007
Last Update Posted: June 25, 2009
PDL BioPharma, Inc.
Information provided by:
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
|Intravenous Steroid-Refractory Ulcerative Colitis||Drug: Visilizumab (HuM291; Nuvion®)||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Facet Biotech:
Contacts and Locations
No Contacts or Locations Provided